204 related articles for article (PubMed ID: 226307)
1. [Effect of a new synthetic compound (3-nicotinoyl-oxypropyl p-chlorophenoxy isobutyrate: I.612) on plasma lipids in patients with type IIa, IIb and IV hyperdyslipidemia].
Bucalossi A; Buzzelli G; D'Alessandro A
Clin Ter; 1979 Apr; 89(2):127-49. PubMed ID: 226307
[No Abstract] [Full Text] [Related]
2. Clofibrate and related compounds in hyperlipoproteinaemia. A review.
Gustafson A
Postgrad Med J; 1975; 51(8):suppl 66-71. PubMed ID: 215983
[No Abstract] [Full Text] [Related]
3. Effect of hypolipidemic drugs on serum lipoproteins.
Carlson LA; Olsson AG
Prog Biochem Pharmacol; 1979; 15():238-57. PubMed ID: 224397
[No Abstract] [Full Text] [Related]
4. Treatment of hyperlipidemia.
Levy RI; Morganroth J; Rifkind BM
N Engl J Med; 1974 Jun; 290(23):1295-301. PubMed ID: 4363888
[No Abstract] [Full Text] [Related]
5. [Comparative studies on the cholesterol and triglyceride-lowering effect of alpha-methylthyroxine (Skleronorm) and clofibrate (Regelan) in hyperlipoproteinemias of type IIa/b and IV].
Jantke J; Schwartzkopff W; Zschiedrich M
Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():392-5. PubMed ID: 206057
[No Abstract] [Full Text] [Related]
6. Atilipidemic drugs. Part 5: Evaluation of the hypolipidemic effect of LF 178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb and IV).
Rouffy J; Dreux C; Goussault Y; Dakkak R; Renson FJ
Arzneimittelforschung; 1976; 26(5):901-6. PubMed ID: 183788
[TBL] [Abstract][Full Text] [Related]
7. [Preliminary study of the tolerance of 3-nicotinoyl-oxypropyl p-chlorophenoxy isobutyrate (I. 612) and on its effects on plasma lipid pattern, hemostasis and clotting-fibrinolysis balance].
Buzzelli G; Doni A; Lippi G; Resina A
Clin Ter; 1979 May; 89(3):251-66. PubMed ID: 466976
[No Abstract] [Full Text] [Related]
8. A physician's guide to hyperlipidemia.
Fredrickson DS
Mod Concepts Cardiovasc Dis; 1972 Jul; 41(7):31-6. PubMed ID: 4343098
[No Abstract] [Full Text] [Related]
9. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E
Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
[TBL] [Abstract][Full Text] [Related]
10. [Current trends in the therapy of arteriosclerotic disease].
Toscano S
G Clin Med; 1974 Jan; 55(1):27-39. PubMed ID: 4369524
[No Abstract] [Full Text] [Related]
11. [Treatment of various types of hyperlipoproteinaemia with a combination of Mg-chlorophenoxy-isobutyrate and mesoinositol-hexanicotinate (author's transl)].
Bolzano K; Krempler F; Haslauer F
Arzneimittelforschung; 1979; 29(10):1621-4. PubMed ID: 583231
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].
Arntz HR; Klemens UH; Vollmar LJ; Lang PD
Med Klin; 1978 Dec; 73(49):1731-7. PubMed ID: 723760
[TBL] [Abstract][Full Text] [Related]
13. [Comparison between combination therapy with clofibrate and beta-pyridylcarbinol and clofibrate monotherapy (author's transl].
Mordasini R; Müller A; Klose G; Middelhoff G; Augustin J; Haase W; Greten H
MMW Munch Med Wochenschr; 1978 Apr; 120(15):525-8. PubMed ID: 206826
[TBL] [Abstract][Full Text] [Related]
14. [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
Schneider J; Mühlfellner G; Mühlfellner O; Hausmann L; Schubotz R
Arzneimittelforschung; 1980; 30(11b):2059-62. PubMed ID: 7194060
[TBL] [Abstract][Full Text] [Related]
15. Effect of calcium p-chlorphenoxyisobutyrate and calcium carbonate on plasma lipids and lipoproteins of patients with hyperlipoproteinaemia.
Koskinen P; Inkovaara J; Ala-Kaila K; Salo M; Nikkari T
Ann Clin Res; 1977 Dec; 9(6):335-41. PubMed ID: 356720
[TBL] [Abstract][Full Text] [Related]
16. [The effect of etofibrate on serum cholesterol and triglycerides (author's transl)].
Dimroth H
Med Klin; 1979 Jun; 74(22):875-6. PubMed ID: 470785
[TBL] [Abstract][Full Text] [Related]
17. [Lipid depression by etofibrate in a comparative study in rats with artificial hyperlipidemia].
Sterner W; Schultz A
Arzneimittelforschung; 1974 Dec; 24(12):1990-2. PubMed ID: 4480360
[No Abstract] [Full Text] [Related]
18. Effects of clofibrate, nicotinic acid and diet on the properties of the plasma lipoproteins in a subject with type III hyperlipoproteinemia.
Patsch JR; Yeshurun D; Jackson RL; Gotto AM
Am J Med; 1977 Dec; 63(6):1001-9. PubMed ID: 204188
[No Abstract] [Full Text] [Related]
19. [The problem of type changes in hyperlipoproteinemia (type IIb, IV, V) under clofibrate and m-inositol nicotinate therapy].
Schwartzkopff W; Zschiedrich M
Verh Dtsch Ges Inn Med; 1976; 82 Pt 1():825-9. PubMed ID: 196436
[No Abstract] [Full Text] [Related]
20. [Multicenter clinical, double blind, and randomized study to assess the effectiveness and safety of binifibrate versus gemfibrozil in type IIa, IIb, and IV hyperlipidemia].
Corominas Vilardell A; de Oya Otero M; Escobar Jiménez F; Anguera Vila A; Ariño Armengol B
An Med Interna; 1993 Nov; 10(11):537-41. PubMed ID: 8117868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
